ანოტაცია
*
წყაროები
1. Alper KR, Lotsof HS, Kaplan CD. „The ibogaine medical subculture.J Ethnopharmacol.” 2008 Jan 4;115(1):9-24. doi: 10.1016/j.jep.2007.08.034. Epub 2007 Aug 25.PMID: 18029124;
2. Alper, K. R., Beal, D., & Kaplan, C. D. (2001). A contemporary history of ibogaine in the United States and Europe. The Alkaloids. Chemistry and Biology, 56, 249-281;
3. Alper, K. R., & Lotsof, H. S. (2007). The use of ibogaine in the treatment of addictions. In M. Winkelman & T. Robert (Eds.), Psychedelic medicine: New evidence for hallucinogenic substances as treatments (Vol. 2, pp. 43-66). Westport, CT: Praeger Perspectives;
4. Alper, K. R., Lotsof, H. S., Frenken, G. M., Luciano, D. J., & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions, 8(3), 234-242. doi:10.1080/105504999305848;
5. Andersen, J. M., Olaussen, C. F., Ripel, Å., & Mørland, J. (2011). Long-term methadone treatment impairs novelty preference in rats both when present and absent in brain tissue. Pharmacology, Biochemistry, and Behavior, 98, 412-416. doi:10.1016/j.pbb.2011.02.017;
6. Bastiaans, E. (2004). Life after ibogaine: An exploratory study of the long-term effects of ibogaine treatment on drug addicts. Retrieved from www.ibogaine.desk.nl/ibogaine_udi_bastiaans.pdf;
7. Bogenschutz, M. P., & Johnson, M. W. (2016). Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 64, 250-258. doi:10.1016/j.pnpbp.2015.03.002;
8. Brown, T. K. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews, 6, 3-16. doi:10.2174/15672050113109990001;
9. Center for Disease Control and Prevention. (2016). Drug overdose deaths in the United States hit record numbers in 2014. Retrieved from https://www.cdc.gov/drugoverdose/epidemic/
10. Degenhardt, L., Charlson, F., Mathers, B., Hall, W. D., Flaxman, A. D., Johns, N., & Vos, T. (2014). The global epidemiology and burden of opioid dependence: Results from the global burden of disease 2010 study. Addiction, 109(8), 1320-1333. doi:10.1111/add.12551;
11. Fernandez, J. W. (1982). Bwiti: An ethnography of the religious imagination in Africa. Princeton, NJ: Princeton University Press;
12. Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., Hung, C. T., Harland, S., Devane, J., Crockett, R. S., Howes, J., Darpo, B., Zhou, M., Weis, H., & Friedhoff, L. (2016). Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development, 5(6), 460-468. doi:10.1002/cpdd.254;
13. Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C. T., & Friedhoff, L. (2015). Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 55(2), 189-194. doi:10.1002/jcph.404;
14. Goutarel, R., Gollnhofer, O., & Sillans, R. (1993). Pharmacodynamics and therapeutic applications of iboga and ibogaine. Psychedelic Monographs and Essays, 6, 70-111;
15. Ling, W., & Compton, P. (2005). Recent advances in the treatment of opiate addiction. Clinical Neuroscience Research, 5(2-4), 161-167. doi:10.1016/j.cnr.2005.08.012;
16. Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the Depression Anxiety Stress Scales (2nd ed.). Sydney, Australia: Psychology Foundation;
17. Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R., Ervin, F. R., Kamlet, J. D., & Hearn, W. L. (2001). Ibogaine in the treatment of heroin withdrawal. The Alkaloids. Chemistry and Biology, 56, 155-171;
18. Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009). Opioid dependence treatment: Options in pharmacotherapy. Expert Opinion on Pharmacotherapy, 10(11), 1727-1740. doi:10.1517/14656560903037168;
19. Tennant, F. (2013). Improvement in physiologic but not hormonal functions after 10 years of opioid treatment. In 29th Annual Meeting of the American Academy of Pain Medicine (AAPM), Fort Lauderdale, FL.